The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Comprehensive molecular portraits of human breast tumours
Open accessAbstract
We analysed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase protein arrays. Our ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers; however, there were numerous subtype-associated and novel gene mutations including the enrichment of specific mutations in GATA3, PIK3CA and MAP3K1 with the luminal A subtype. We identified two novel protein-expression-defined subgroups, possibly produced by stromal/microenvironmental elements, and integrated analyses identified specific signalling pathways dominant in each molecular subtype including a HER2/phosphorylated HER2/EGFR/phosphorylated EGFR signature within the HER2-enriched expression subtype. Comparison of basal-like breast tumours with high-grade serous ovarian tumours showed many molecular commonalities, indicating a related aetiology and similar therapeutic opportunities. The biological finding of the four main breast cancer subtypes caused by different subsets of genetic and epigenetic abnormalities raises the hypothesis that much of the clinically observable plasticity and heterogeneity occurs within, and not across, these major biological subtypes of breast cancer. The Cancer Genome Atlas Network describe their multifaceted analyses of primary breast cancers, shedding light on breast cancer heterogeneity; although only three genes (TP53, PIK3CA and GATA3) are mutated at a frequency greater than 10% across all breast cancers, numerous subtype-associated and novel mutations were identified. This Article from the Cancer Genome Atlas consortium describes a multifaceted analysis of primary breast cancers in 825 people. Exome sequencing, copy number variation, DNA methylation, messenger RNA arrays, microRNA sequencing and proteomic analyses were performed and integrated to shed light on breast-cancer heterogeneity. Just three genes — TP53, PIK3CA and GATA3 — are mutated at greater than 10% frequency across all breast cancers. Many subtype-associated and novel mutations were identified, as well as two breast-cancer subgroups with specific signalling-pathway signatures. The analyses also suggest that much of the clinically observable plasticity and heterogeneity occurs within, and not across, the major subtypes of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoxia-inducible factor 1α (HIF-1α) is a master transcription factor that is highly expressed in cancer tissues, including breast cancer, and is particularly enriched in triple-negative breast cancer (TNBC)2.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“A recent analysis, combining mutation, mRNA expression and protein levels, determined that the PI3K/Akt pathway was elevated in basal-like cancers as compared with luminal or HER2+ (47).”
From Mislocalization of the Cell Polarity Protein Scribble Promotes Mammary Tumorigenesis and Is Associated with Basal Breast Cancer (2014) · cites this paper as [47]
In the citing paper
“In breast cancer, hypoxia is more evident in TNBC than in other breast cancer subtypes11,12.”
In the citing paper
“data analysis of The Cancer Genome Atlas (TCGA) dataset11 identified that hypoxic gene signature, which includes commonly documented hypoxia-responsive genes26, was inversely correlated with immune effector genes (IFNG, TNF, GZMB, PRF1), IFNγ-responsive genes, as well as genes associated with tumor-infiltrating lymphocytes (TILs) in TNBC (n = 99) (also referred as a basal subtype of breast cancer)”
In the citing paper
“Kaplan–Meier analysis using public breast cancer meta-analysis database11,30 reveals that TNBC patients with higher hypoxia gene signature are associated with worse disease outcomes, including both overall survival (OS) and distant metastasis-free survival (DMFS), compared to those with lower expression of hypoxia gene signature (Fig. 1h).”
In the citing paper
“Analysis of hundreds of triple-negative breast cancers revealed a wide diversity of somatic mutations none of which were found at high frequency [4].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [4]
In the citing paper
“Given the remarkable overexpression of HIF target genes in triple-negative breast cancer [4, 21], the master regulatory role of HIFs in metastasis (Fig. 5), and their involvement in chemotherapy resistance, HIF inhibitors may represent a targeted therapy for these breast cancers.”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Self-citationA Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J. B., Cronin, M. T., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,321
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,508
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,085
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
Best, M. G., Sol, N., Kooi, I. E., Tannous, J. M., Westerman, B. A., Rustenburg, F., Schellen, P., Verschueren, H., Post, E., Köster, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.018 · Cited by 945
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
Interplay between the Cancer Genome and Epigenome
Shen, H., & Laird, P. W. (2013) · Cell · doi:10.1016/j.cell.2013.03.008 · Cited by 949
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Collier, M. D., Desai, R. N., Zhu, H., Comaills, V., Zheng, Z., et al. (2014) · Science · doi:10.1126/science.1253533 · Cited by 927
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Ceccaldi, R., Liu, J., Amunugama, R., Hajdú, I., Primack, B., Petalcorin, M. I. R., O’Connor, K. W., Konstantinopoulos, P. A., Elledge, S. J., Boulton, S. J., et al. (2015) · Nature · doi:10.1038/nature14184 · Cited by 945
Chen, Y., Chen, L., Lun, A. T. L., Baldoni, P. L., & Smyth, G. K. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf018 · Cited by 951
Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes
Gao, R., Bai, S., Henderson, Y. C., Lin, Y., Schalck, A. P., Yan, Y., Kumar, T., Hu, M. S., Sei, E., Davis, A., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-00795-2 · Cited by 924
Leiserson, M. D. M., Vandin, F., Wu, H.-T., Dobson, J. R., Eldridge, J. V., Thomas, J. L., Papoutsaki, A., Kim, Y., Niu, B., McLellan, M. D., et al. (2014) · Nature Genetics · doi:10.1038/ng.3168 · Cited by 922
Triple negative breast cancer: Pitfalls and progress
Zagami, P., & Carey, L. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00468-0 · Cited by 954
Triple-negative breast cancer in African-American women: disparities versus biology
Dietze, E. C., Sistrunk, C., Miranda‐Carboni, G. A., O'Regan, R. M., & Seewaldt, V. L. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3896 · Cited by 912
The single-cell pathology landscape of breast cancer
Jackson, H. W., Fischer, J. R., Zanotelli, V. R., Ali, H. R., Mechera, R., Soysal, S. D., Moch, H., Muenst, S. E., Varga, Z., Weber, W. P., et al. (2020) · Nature · doi:10.1038/s41586-019-1876-x · Cited by 892
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890
Breast cancer intrinsic subtype classification, clinical use and future trends.
Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., & Shi, B. (2015) · Europe PMC (PubMed Central) · Cited by 888
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
Corsello, S. M., Nagari, R. T., Spangler, R. D., Rossen, J., Kocak, M., Bryan, J. G., Humeidi, R., Peck, D., Wu, X., Tang, A. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0018-6 · Cited by 878
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Damrauer, J. S., Hoadley, K. A., Chism, D. D., Fan, C., Tiganelli, C. J., Wobker, S. E., Yeh, J. J., Milowsky, M. I., Iyer, G., Parker, J. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318376111 · Cited by 901
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
Denkert, C., Liedtke, C., Tutt, A. N. J., & von Minckwitz, G. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32454-0 · Cited by 897
Chaffer, C. L., Marjanovic, N. D., Lee, T., Bell, G. W., Kleer, C. G., Reinhardt, F., D’Alessio, A. C., Young, R. A., & Weinberg, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.06.005 · Cited by 903
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J. D., Goel, N. J., Aronson, A. B., Li, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 886
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer
Bassez, A., Vos, H., Van Dyck, L., Floris, G., Arijs, I., Desmedt, C., Boeckx, B., Vanden Bempt, M., Nevelsteen, I., Lambein, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01323-8 · Cited by 867
The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 887
Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis
Clarke, C., Madden, S. F., Doolan, P., Aherne, S. T., Joyce, H., O’Driscoll, L., Gallagher, W. M., Hennessy, B. T., Moriarty, M. J., Crown, J. P., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt208 · Cited by 854
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
Davis, C., Ricketts, C. J., Wang, M., Yang, L., Cherniack, A. D., Shen, H., Buhay, C., Kang, H.-J., Kim, S. C., Fahey, C. C., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.014 · Cited by 854
The PI3K/AKT Pathway as a Target for Cancer Treatment
Mayer, I. A., & Arteaga, C. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 833
Bartoschek, M., Oskolkov, N., Bocci, M., Lövrot, J., Larsson, C., Sommarin, M., Madsen, C. D., Lindgren, D., Pekar, G., Karlsson, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07582-3 · Cited by 826
APOBEC3B is an enzymatic source of mutation in breast cancer
Burns, M. B., Lackey, L., Carpenter, M. A., Rathore, A. S., Land, A. M., Leonard, B. C., Refsland, E. W., Kotandeniya, D., Tretyakova, N. Y., Nikas, J. B., et al. (2013) · Nature · doi:10.1038/nature11881 · Cited by 835
Bresnick, A. R., Weber, D. J., & Zimmer, D. B. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3893 · Cited by 819
XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway
Chen, X., Iliopoulos, D., Zhang, Q. H., Tang, Q., Greenblatt, M. B., Hatziapostolou, M., Lim, E., Tam, W. L., Ni, M., Chen, Y., et al. (2014) · Nature · doi:10.1038/nature13119 · Cited by 840
Davoli, T., Xu, A. W., Mengwasser, K. E., Sack, L. M., Yoon, J. C., Park, P. J., & Elledge, S. J. (2013) · Cell · doi:10.1016/j.cell.2013.10.011 · Cited by 815
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214131 · Cited by 813
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
Yates, L. R., Gerstung, M., Knappskog, S., Desmedt, C., Gundem, G., Loo, P. V., Aas, T., Alexandrov, L. B., Larsimont, D., Davies, H., et al. (2015) · Nature Medicine · doi:10.1038/nm.3886 · Cited by 833
mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle
Ben-Sahra, I., Hoxhaj, G., Ricoult, S. J. H., Asara, J. M., & Manning, B. D. (2016) · Science · doi:10.1126/science.aad0489 · Cited by 795
Zhang, Y., Chen, H., Mo, H., Hu, X., Gao, R., Zhao, Y., Liu, B., Niu, L., Sun, X., Yu, X., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.010 · Cited by 783
An overview of triple-negative breast cancer
Kumar, P. V., & Aggarwal, R. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3859-y · Cited by 779
Zacharakis, N., Chinnasamy, H., Black, M. A., Xu, H., Lu, Y., Zheng, Z., Pasetto, A., Langhan, M. M., Shelton, T. E., Prickett, T. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0040-8 · Cited by 786
Herrera-Abreu, M. T., Palafox, M., Asghar, U. S., Rivas, M. A., Cutts, R. J., García-Murillas, I., Pearson, A., Guzmán, M., Rodríguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 781
A community effort to assess and improve drug sensitivity prediction algorithms
Community, N. D., Costello, J. C., Heiser, L. M., Georgii, E., Gönen, M., Menden, M. P., Wang, N. J., Bansal, M., Ammad-ud-din, M., Hintsanen, P., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2877 · Cited by 782
Deciphering breast cancer: from biology to the clinic
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 792
Lánczky, A., Nagy, Á. M., Bottai, G., Munkácsy, G., Szabó, A., Santarpia, L., & Győrffy, B. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4013-7 · Cited by 759
Long noncoding RNA MALAT1 suppresses breast cancer metastasis
Kim, J., Piao, H.-L., Kim, B., Yao, F., Han, Z., Wang, Y., Xiao, Z., Siverly, A. N., Lawhon, S. E., Ton, B. N., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0252-3 · Cited by 767
Evaluation of variable selection methods for random forests and omics data sets
Degenhardt, F. C., Seifert, S., & Szymczak, S. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx124 · Cited by 749
Network-based stratification of tumor mutations
Hofree, M., Shen, J. P., Carter, H. K., Gross, A. M., & Ideker, T. (2013) · Nature Methods · doi:10.1038/nmeth.2651 · Cited by 747
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
Jeselsohn, R. M., Buchwalter, G., Angelis, C. D., Brown, M. A., & Schiff, R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.117 · Cited by 744
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722
Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue
Gerdes, M. J., Sevinsky, C. J., Sood, A., Adak, S., Bello, M. O., Bordwell, A., Can, A. B., Corwin, A. D., Dinn, S. R., Filkins, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300136110 · Cited by 716
Pathogenesis of Triple-Negative Breast Cancer
Derakhshan, F., & Reis-Filho, J. S. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042420-093238 · Cited by 714
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity
Spinner, M. A., Sanchez, L. A., Hsu, A. P., Shaw, P. A., Zerbe, C. S., Calvo, K. R., Arthur, D. C., Gu, W., Gould, C. M., Brewer, C. C., et al. (2013) · Blood · doi:10.1182/blood-2013-07-515528 · Cited by 713
Genomic characterization of metastatic breast cancers
Bertucci, F., Ng, C. K. Y., Patsouris, A., Droin, N. M., Piscuoglio, S., Carbuccia, N., Soria, J., Dien, A. T., Adnani, Y., Kamal, M. T., et al. (2019) · Nature · doi:10.1038/s41586-019-1056-z · Cited by 723
EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration
Aiello, N. M., Maddipati, R., Norgard, R. J., Balli, D., Li, J., Yuan, S., Yamazoe, T., Black, T. A., Sahmoud, A., Furth, E. E., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.05.027 · Cited by 734
Andreu-Pérez, J., Poon, C. C. Y., Merrifield, R. D., Wong, S. T. C., & Yang, G. (2015) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2015.2450362 · Cited by 728
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695
Forkhead box proteins: tuning forks for transcriptional harmony.
Lam, E. W.-F., Brosens, J. J., Gomes, A. R., & Koo, C.-Y. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3539 · Cited by 684
RNA splicing factors as oncoproteins and tumour suppressors
Dvinge, H., Kim, E. H., Abdel-Wahab, O. I., & Bradley, R. K. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.51 · Cited by 706
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Schettini, F., Chic, N., Brasó‐Maristany, F., Paré, L., Pascual, T., Conte, B., Martínez‐Sáez, O., Adamo, B., Vidal, M. J., Barnadas, E., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-020-00208-2 · Cited by 687
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
Bonapace, L., Coissieux, M., Wyckoff, J. B., Mertz, K. D., Varga, Z., Junt, T., & Bentires‐Alj, M. (2014) · Nature · doi:10.1038/nature13862 · Cited by 698
Aguirre‐Gamboa, R., Gómez-Rueda, H., Martínez-Ledesma, E., Martínez‐Torteya, A., Chacolla-Huaringa, R., Rodriguez-Barrientos, A., Tamez‐Peña, J. G., & Treviño, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074250 · Cited by 679
Zitnik, M., Nguyen, F., Wang, B., Leskovec, J., Goldenberg, A., & Hoffman, M. M. (2019) · Information Fusion · doi:10.1016/j.inffus.2018.09.012 · Cited by 675
Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2332 · Cited by 674
Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P. L., Olson, J. E., Godwin, A. K., Pankratz, V. S., Olswold, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1414 · Cited by 673
Wang, T., Shao, W., Huang, Z., Tang, H., Zhang, J., Ding, Z., & Huang, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23774-w · Cited by 671
Genomic Evolution of Breast Cancer Metastasis and Relapse
Yates, L. R., Knappskog, S., Wedge, D. C., Farmery, J. H. R., González, S., Martincorena, I., Alexandrov, L. B., Loo, P. V., Haugland, H. K., Lilleng, P. K., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.005 · Cited by 683
Pan-cancer image-based detection of clinically actionable genetic alterations
Kather, J. N., Heij, L. R., Grabsch, H. I., Loeffler, C. M. L., Echle, A., Muti, H. S., Krause, J., Niehues, J., Sommer, K. A. J., Bankhead, P., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0087-6 · Cited by 686
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
A DNA methylation atlas of normal human cell types
Loyfer, N., Magenheim, J., Peretz, A., Cann, G., Bredno, J., Klochendler, A., Fox-Fisher, I., Shabi-Porat, S., Hecht, M., Pelet, T., et al. (2023) · Nature · doi:10.1038/s41586-022-05580-6 · Cited by 656
O’Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., García-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 657
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 676
Yang, F., Xiao, Y., Ding, J.-H., Jin, X., Ma, D., Li, D., Shi, J., Huang, W. C., Wang, Y.-P., Jiang, Y., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.021 · Cited by 649
MicroRNA Related Polymorphisms and Breast Cancer Risk
Khan, S., Greco, D., Michailidou, K., Milne, R. L., Muranen, T., Heikkinen, T., Aaltonen, K., Dennis, J., Bolla, M. K., Liu, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109973 · Cited by 639
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 652
The lingering mysteries of metastatic recurrence in breast cancer
Riggio, A. I., Varley, K. E., & Welm, A. L. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01161-4 · Cited by 656
Giger (2018) · doi:10.1016/j.jacr.2017.12.028 · Cited by 634
Ding, L., Cao, J., Lin, W.-S., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., & Cui, Q. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061960 · Cited by 655
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes
Stanton, S. E., Adams, S., & Disis, M. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1061 · Cited by 647
The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications
Linehan, W. M., & Ricketts, C. J. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0211-5 · Cited by 644
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626
Classification of triple-negative breast cancers based on Immunogenomic profiling
He, Y., Jiang, Z., Chen, C., & Wang, X. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1002-1 · Cited by 633
André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.011 · Cited by 624
Li, S., Shen, D., Shao, J., Crowder, R. J., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 637
Comprehensive analysis of normal adjacent to tumor transcriptomes
Aran, D., Camarda, R., Odegaard, J. I., Paik, H., Oskotsky, B., Krings, G., Goga, A., Sirota, M., & Butte, A. J. (2017) · Nature Communications · doi:10.1038/s41467-017-01027-z · Cited by 620
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2994 · Cited by 618
Kraft, J. C., Freeling, J. P., Wang, Z., & Ho, R. J. Y. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23773 · Cited by 614
Ali, H. R., Chlon, L., Pharoah, P. D. P., Markowetz, F. M., & Caldas, C. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002194 · Cited by 619
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy
Mack, S. C., Witt, H., Piro, R. M., Gu, L., Zuyderduyn, S., Stütz, A. M., Wang, X., Gallo, M., Garzia, L., Zayne, K., et al. (2014) · Nature · doi:10.1038/nature13108 · Cited by 607
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers
Berger, A. C., Korkut, A., Kanchi, R. S., Hegde, A. M., Lenoir, W. F., Liu, W., Liu, Y., Fan, H., Shen, H., Ravikumar, V., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.014 · Cited by 621
Breast Cancer: Current Perspectives on the Disease Status
Ullah, M. F. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-20301-6_4 · Cited by 601
A pan-cancer proteomic perspective on The Cancer Genome Atlas
Akbani, R., Ng, P. K. S., Werner, H. M. J., Shahmoradgoli, M., Zhang, F., Ju, Z., Liu, W., Yang, J.-Y., Yoshihara, K., Li, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms4887 · Cited by 616
Deciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 626
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers
Gao, Q., Liang, W.-W., Foltz, S. M., Mutharasu, G., Jayasinghe, R. G., Cao, S., Liao, W., Reynolds, S. M., Wyczalkowski, M. A., Yao, L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.050 · Cited by 608
BOCS, Michailidou, K., kConFab Investigators, AOCS Group, NBCS, GENICA Network, Beesley, J., Lindström, S., Canisius, S., Dennis, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3242 · Cited by 598
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Paplomata, E., & O'Regan, R. M. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014530023 · Cited by 610
Schiavon, G., Hrebien, S., García-Murillas, I., Cutts, R. J., Pearson, A., Tarazona, N., Fenwick, K., Kozarewa, I., López‐Knowles, E., Ribas, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7551 · Cited by 602
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survivalPreprint
Brown, S. D., Warren, R. M., Gibb, E. A., Martin, S. D., Spinelli, J. J., Nelson, B. H., & Holt, R. A. (2014) · Genome Research · doi:10.1101/gr.165985.113 · Cited by 601
Therapeutic opportunities within the DNA damage response
Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. G. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3891 · Cited by 587
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
Eirew, P. D., Steif, A., Khattra, J. S., Ha, G., Yap, D., Farahani, H., Gelmon, K. A., Chia, S., Mar, C., Wan, A., et al. (2014) · Nature · doi:10.1038/nature13952 · Cited by 599
Molecular Classification of Breast Cancer
Tsang, J. Y., & Tse, G. M.-K. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000232 · Cited by 574
Clinical management of breast cancer heterogeneity
Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 581
Tumor Heterogeneity in Breast Cancer
Turashvili, G., & Brogi, E. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00227 · Cited by 571
[Retracted] Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures
Kashyap, D., Pal, D., Sharma, R., Garg, V. K., Goel, N., Koundal, D., Zaguia, A., Koundal, S., & Belay, A. (2022) · BioMed Research International · doi:10.1155/2022/9605439 · Cited by 604
RetractedVanharanta, S., & Massagué, J. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.007 · Cited by 563
Metadata
- Authors
- The Cancer Genome Atlas Network
- Corresponding author
- The Cancer Genome Atlas Network
- Venue
- Nature
- Published
- 2012-09-23
- Volume
- 490
- Issue
- 7418
- Pages
- 61-70
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3465532
- OpenAlex
- W4301159569
- Cited by
- 12,129
- References
- 56
- Citations by year
- 2026: 552 · 2025: 690 · 2024: 761 · 2023: 781 · 2022: 918 · 2021: 1164 · 2020: 1005 · 2019: 961 · 2018: 942 · 2017: 949 · 2016: 979 · 2015: 909 · 2014: 879 · 2013: 590 · 2012: 40
- FWCI
- 256.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Defense
- Breast Cancer Research Foundation (P50CA116201)
- Henry M. Jackson Foundation
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG004028)
- National Cancer Institute (R01CA094143, U24CA143882, U01CA084955, U24CA143840, U24CA143858, U24CA144025, K08CA148912, U24CA143866, U24CA143883, U24CA143845, U24CA143867, U24CA143848, U24CA143799, U24CA143835, P50 CA 58223, P30CA016672, P30CA016058, P50CA058223, P50CA116201, P30CA016086)
- U.S. National Library of Medicine (R01LM009722)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- breast cancer, molecular subtypes, tumor heterogeneity, somatic mutations, TP53, PIK3CA, GATA3, MAP3K1, luminal A, HER2-enriched breast cancer, basal-like breast cancer, high-grade serous ovarian cancer, DNA methylation, copy number variation, gene expression signatures, signaling pathways, tumor microenvironment, multi-omics integration
- MeSH terms
- Breast Neoplasms, DNA Mutational Analysis, Female, Humans, Mutation, Ovarian Neoplasms, Receptors, Estrogen, RNA, Messenger, RNA, Neoplasm, Genome, Human, Gene Expression Regulation, Neoplastic, Genes, p53, Retinoblastoma Protein, Genes, erbB-2, Genetic Heterogeneity, DNA Methylation, Genes, BRCA1, Phosphatidylinositol 3-Kinases, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Genomics, MicroRNAs, Protein Array Analysis, Proteomics, MAP Kinase Kinase Kinase 1, GATA3 Transcription Factor, Genes, Neoplasm, DNA Copy Number Variations, Class I Phosphatidylinositol 3-Kinases, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
